8-KOther EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Corporate Update (Dec 8, 2020)

Filed December 8, 2020For Securities:ONCBEIGF

Summary

BeOne Medicines Ltd. (ONC) filed an 8-K on December 8, 2020, reporting significant clinical data and regulatory developments. The company presented encouraging data for its BTK inhibitor, BRUKINSA® (zanubrutinib), at the 62nd American Society for Hematology (ASH) Annual Meeting. Key presentations included initial results from the Phase 2 MAGNOLIA trial for relapsed/refractory marginal zone lymphoma (MZL) and follow-up data from the Phase 3 SEQUOIA trial in treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with del(17p). Furthermore, BeOne Medicines announced the approval of BLINCYTO® (blinatumomab) in China for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This marks the first approval for BLINCYTO in China and the first product licensed from Amgen to be approved, positioning BLINCYTO as the first bispecific immunotherapy approved in China. These events highlight progress in the company's oncology pipeline and market expansion.

Key Highlights

  • 1Presentation of clinical data for BRUKINSA® (zanubrutinib) at the 62nd ASH Annual Meeting, focusing on Marginal Zone Lymphoma (MZL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
  • 2Initial results from the Phase 2 MAGNOLIA trial for relapsed/refractory MZL were presented.
  • 3Follow-up results from Arm C of the Phase 3 SEQUOIA trial in treatment-naïve CLL/SLL with del(17p) were shared.
  • 4Clinical data on BRUKINSA® in B-cell malignancies intolerant to other BTK inhibitors (ibrutinib/acalabrutinib) were presented.
  • 5First results from a pivotal Phase 2 trial for BRUKINSA® in relapsed/refractory Waldenström’s Macroglobulinemia (WM) were presented, supporting a China supplemental new drug application.
  • 6Approval of BLINCYTO® (blinatumomab) by China's NMPA for adult R/R B-cell precursor ALL.
  • 7BLINCYTO® is the first bispecific immunotherapy approved in China and BeiGene's first Amgen-licensed product approved in the region.

Frequently Asked Questions

BeiGene presented significant clinical data for BRUKINSA® at the 62nd ASH Annual Meeting. This included initial data from the Phase 2 MAGNOLIA trial in relapsed/refractory marginal zone lymphoma (MZL) and follow-up results from the Phase 3 SEQUOIA trial in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with del(17p). Data were also presented for patients intolerant to other BTK inhibitors and for Waldenström’s Macroglobulinemia (WM).

The approval of BLINCYTO® in China by the NMPA for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) is a major milestone. It represents the first approval for BLINCYTO in China, the first product licensed from Amgen to be newly approved by BeiGene in China, and makes BLINCYTO the first bispecific immunotherapy approved in the Chinese market.

These announcements demonstrate substantial progress in BeiGene's oncology pipeline and commercial strategy. The positive clinical data for BRUKINSA® could support its ongoing development and potential future regulatory submissions and market adoption. The BLINCYTO® approval in China opens a new market and expands the company's portfolio of approved therapies in a key region, showcasing the value of its strategic collaborations.